Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension
Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.
Pharma & Biotech